|
Immune Abnormalities in Sporadic Inclusion Body Myositis Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Immune Abnormalities in Sporadic Inclusion Body Myositis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Immune Abnormalities in Sporadic Inclusion Body Myositis Clinical research trials and Immune Abnormalities in Sporadic Inclusion Body Myositis health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Immune Abnormalities in Sporadic Inclusion Body Myositis. Immune Abnormalities in Sporadic Inclusion Body Myositis Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Immune Abnormalities in Sporadic Inclusion Body Myositis clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Immune Abnormalities in Sporadic Inclusion Body Myositis condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Immune Abnormalities in Sporadic Inclusion Body Myositis  Immune Abnormalities in Sporadic Inclusion Body Myositis
Immune Abnormalities in Sporadic Inclusion Body Myositis
For Condition: Sporadic,Myositis,Inclusion Body
Status: Recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: This study will examine the abnormal immune response in patients with sporadic inclusion body myositis (s-IBM)-the most common inflammatory muscle disease in people over the age of 50. s-IBM progresses steadily and may lead to severe weakness and wasting of arm and leg muscles. Patients may become unable to perform daily living activities and be confined to wheelchairs. s-IBM is thought to be an autoimmune disease, in which the body's own immune system attacks healthy muscles. This study will explore the causes of the muscle tissue inflammation that is responsible for destruction of muscle fibers and weakness in this disease. Information from the study may help in the development of an effective treatment for this disease. Patients with s-IBM may be eligible for this study. Those who are unable to travel or who have severe cardiovascular, renal or other end-stage organ disease will be excluded. Candidates will be screened for eligibility with a medical history and physical and neurological examinations. Participants will be seen at the NIH Clinical Center every six months over a 12-month period (visits at enrollment, 6 months and 12 months) either on an inpatient or outpatient basis, depending on their disease severity. Each 2- to 3-day visit will involve the following tests and evaluations: - Blood samples for routine laboratory tests are collected at every visit. Additional blood for research studies is collected at 12 months. - Quantitative muscle strength testing is done at every visit. The patient pulls against straps connected to dynamometers (devices that measure muscle power) to evaluate strength of the main muscle groups in the arms and legs. - Lymphapheresis is done at enrollment and at 12 months. This is a procedure for collecting quantities of lymphocytes (white blood cells that are an important part of the immune system). Blood is collected through a needle placed in an arm vein and circulated through a machine that spins it, separating it into its components. The lymphocytes are removed and the rest of the blood (red cells, platelets and plasma) is returned to the body through the same needle or another needle placed in the other arm. - Electrophysiologic studies (electromyography and nerve conduction testing) are done at enrollment and 12 months. Electromyography evaluates the electrical activity of muscles. A small needle is inserted into the muscle and the patient is asked to relax or to contract the muscle. For nerve conduction testing, nerves are stimulated by electrodes (small wires taped to the skin over the muscle). - Muscle biopsy is done at enrollment and 12 months. A sample of muscle tissue (about the size of a lima bean) from an arm or leg is surgically removed to confirm the diagnosis of s-IBM and for analysis of proteins involved in the muscle inflammation process. A local anesthetic is used to numb the area before the surgery and the wound is closed with stitches.
Details: Sporadic Inclusion Body Myositis (s-IBM) is the most common acquired myopathy above the age of 50 years. It is a disabling disease that leads to wheelchair confinement. The cause is unknown but autoimmune mechanisms have been implicated. The primary goal of the study is to search for candidate autoantigen(s) that drive the autoimmune response and identify candidate pathogenic T-cell epitopes among the endomysial T-cells extracted from the patients' muscle biopsies. It is anticipated that the search for the antigens implicated in the clonal expansion of endomysial T-cells over time will elucidate the autoimmune pathogenesis of the disease and lead to the development of antigen-specific immunomodulatory therapeutic strategies. This is an investigative study intended to better define the pathogenesis of s-IBM. No new therapy will be provided except standard of care.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: s-IBM is a chronic inflammatory muscle disorder with marked male preponderance in 60% to 75% of cases. The onset of the disease is usually after the fifth decade. Although there have been reports of autosomal dominant and autosomal recessive familial cases of the disease, the sporadic form is believed to account for the vast majority of known cases. Enrolled patients should fulfill the clinical and laboratory criteria of s-IBM. EXCLUSION CRITERIA: Will be excluded from this study with: Very advanced disease state that precludes from traveling; Severe cardiovascular, renal, or other end-organ-disease states.
Total Enrollment: 80
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020121; 02-N-0121
Study Start Date: February 4, 2002
Record last reviewed: January 29, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00030212
Other Sporadic Studies:
1. Immune Abnormalities in Sporadic Inclusion Body Myositis
Related Studies:
Other Sporadic Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Immune Abnormalities in Sporadic Inclusion Body Myositis
|
|
|
|
|
|
|
|
